1
* Not all systems shown available worldwide.
2
Budi Gunadi Sadikin
Minister of Health
Republic of Indonesia
3
Historial del programa
2006
Cepheid crea los primeros sistemas de [genexpert]GeneXpert®
2006
La OMS lanza la Estrategia para la detención de la tuberculosis en el Día Mundial de la TB
2006
Cepheid, FIND, University of Medicine and Dentistry of New Jersey (Rutgers University), and NIAID collaborate to develop Xpert® MTB/RIF* for TB with a grant from the Bill & Melinda Gates Foundation
2009–2010
Xpert MTB/RIF* lanza y recibe el respaldo de la OMS
Acceso mundial
2011
Cepheid establece oficialmente el Programa de acceso global
2006
En respuesta a las altas tasas de coinfección por TB-VIH en los países de acceso global, Cepheid y FIND se asocian al desarrollo de la prueba HIV-1viral load* de Xpert.
2014
Xpert® HPV* and Xpert HIV-1 VL* tests launch
2015
Cepheid develops and launches Xpert® Ebola test to respond to West African outbreak with funding support from the Paul G. Allen and Bill & Melinda Gates Foundations
2016
WHO prequalifies Xpert HIV-1 Qual*
2017
WHO prequalifies Xpert HCV VL*, Xpert HIV-1 VL*, and Xpert HPV*; Xpert® MTB/RIF Ultra* launches and gets WHO endorsement
2020
Xpert® MTB/XDR* launches to detect multidrug-resistant TB with new 10-color multiplexing technology
2020
Xpert® Xpress SARS-CoV-2" launches
Programa de acceso global hoy
GeneXpert systems available in multiple modular configuration options 15 tests available under Global Access Program, 7 of which are endorsed or pre-qualified by WHO
* CE-IVD. Producto sanitario para diagnóstico in vitro. Es posible que no esté disponible en todos los países. No disponible en Estados Unidos.
IVD. Producto sanitario para diagnóstico in vitro. Es posible que no esté disponible en todos los países
^ Para uso con una autorización de uso de emergencia en Estados Unidos
Dr. Tereza Kasaeva, Director, Global Tuberculosis Programme, WHO World TB Day 2023, Interview with Dr. Tereza Kasaeva
https://www.youtube.com/watch?v=AL_t8LZkD8Y
2. Journal of Benefit-Cost Analysis (2023) https://www.cambridge.org/core/journals/journal-of-benefit-cost-analysis/article/one-million-lives-saved-per-year-a-costbenefit-analysis-of-the-global-plan-to-end-tuberculosis-20232030-and-beyond/A74F0D10F1017092A250EB604ED39B1B
3. Message from the Executive Director: Global Fund Investments in Health and Laboratory-related Equipment; 21 de enero de 2024
https://www.theglobalfund.org/en/oig/updates/2024-01-26-message-executive-director-global-fund-investments-health-laboratory-related-equipment/
4. Peter Sands, Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria.
From the TB Innovation Summit https://www.stoptb.org/news/global-health-and-business-leaders-pledge-major-commitments-to-end-tuberculosis